Evaluaion the Short Term Effects of Advograf Plus Rapamiune After Kidney Transplantation
Investigating the Effect of Low-dose Extended-release Tacrolimus and Sirolimus on the Short-term Outcomes of Allograft Kidney Transplantation
Shahid Beheshti University of Medical Sciences
50 participants
Mar 1, 2025
INTERVENTIONAL
Conditions
Summary
Cornerstone immunosuppressive therapy currently relies on immediate-release tacrolimus, a calcineurin inhibitor (CNI) that is potentially nephrotoxic and is more diabetogenic than cyclosporine A. A new formulation of tacrolimus has been launched: an extended-release formulation (Advagraf®/Astagraf XL®, Astellas company).
Eligibility
Inclusion Criteria1
- All Kidney transplant recipients
Exclusion Criteria1
- Kidney-Pancreas transplant BMI>30 cPRA>0%
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Rapamiune Tablet 1mg daily plus Advograf plus prednisolone
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07033858